Abstract
Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 67-70 |
| Number of pages | 4 |
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1982 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer : a phase II trial of the EORTC breast cancer cooperative group. / Paridaens, R.; Mouridsen, H. T.; Palshof, T.; Cocconi, G.; van Oosterom, A.; Rotmensz, N.; Sylvester, R.; Heuson, J. C.; Rozencweig, M.
In: European Journal of Cancer and Clinical Oncology, Vol. 18, No. 1, 1982, p. 67-70.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer
T2 - a phase II trial of the EORTC breast cancer cooperative group
AU - Paridaens, R.
AU - Mouridsen, H. T.
AU - Palshof, T.
AU - Cocconi, G.
AU - van Oosterom, A.
AU - Rotmensz, N.
AU - Sylvester, R.
AU - Heuson, J. C.
AU - Rozencweig, M.
PY - 1982
Y1 - 1982
N2 - Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.
AB - Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0020035037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020035037&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(82)90026-8
DO - 10.1016/0277-5379(82)90026-8
M3 - Article
C2 - 6211361
AN - SCOPUS:0020035037
VL - 18
SP - 67
EP - 70
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 1
ER -